Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 152

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 152
---
 ended, incorporated by reference into this prospectus and in the registration
statement, have been so incorporated in reliance on a report of Forvis Mazars LLP (then-named Mazars LLP), an independent registered accounting
firm, given on authority of said firm as experts in auditing and accounting. The report on the financial statements for the year ended
December 31, 2023 contains an explanatory paragraph in Note 2 regarding our ability to continue as a going concern.

Forvis Mazars LLP, London, United Kingdom,
is a member of the Institute of Chartered Accountants in England and Wales.

<div align='center'>WHERE YOU CAN FIND MORE INFORMATION</div>

We are subject to periodic reporting and
other informational requirements of the Exchange Act, as applicable to foreign private issuers. Accordingly, we are required to file reports,
including annual reports on Form 20-F, and other information with the SEC. As a foreign private issuer, we are exempt from the rules of
the Exchange Act prescribing the furnishing and content of proxy statements to shareholders under the federal proxy rules contained in
Sections 14(a), (b) and (c) of the Exchange Act, and our “insiders” are exempt from the reporting and short-swing
profit recovery provisions contained in Section 16 of the Exchange Act. The SEC maintains an Internet site that contains reports,
proxy, information statements and other information regarding issuers at http://www.sec.gov. Copies of certain information filed by us
with the SEC are also available on our website at http://www.biodexapharma.com. Our website is not a part of this prospectus and is not
incorporated by reference in this prospectus.

This prospectus is part of a registration
statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance with SEC
rules and regulations. You should review the information and exhibits in the registration statement for further information on us
and our consolidated subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed as
an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified
by reference to these filings. You should review the complete document to evaluate these statements. You can obtain a copy of the registration
statement from the SEC at the address listed above or from the SEC’s website.

<div align='center'>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</div>

The SEC allows us